Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Iovance Biotherapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 255 | 3 | 253 | +1 |
| Shares | 220.3M | 80.4K | 213.0M | −7.19M (−3.3%) |
| Value | $379.3M | $138.4K | $462.3M | +$83.1M (+21.9%) |
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (41)
Institutions that held Iovance Biotherapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (40)
Institutions that held Iovance Biotherapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (3)
Institutions that held Iovance Biotherapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| E Fund Management Co., Ltd. | 32,559 | $56.0K |
| CIBC World Markets Corp | 31,589 | $54.3K |
| Avantax Advisory Services, Inc. | 16,299 | $28.0K |